Saturday, July 6, 2019

Data demonstrate efficacy of more flexible dose of regorafenib to relieve side-effects in mCRC patients

Some of the adverse events related to the use of regorafenib often limits its use in clinical practice. A study suggests the usefulness of a more flexible dosing, which improves patients’ quality of life without jeopardizing efficacy.

from https://www.sciencedaily.com/releases/2019/07/190706123457.htm



from
https://healthnews010.tumblr.com/post/186109420243

from https://johnher1.blogspot.com/2019/07/data-demonstrate-efficacy-of-more.html

from
https://johnher10.tumblr.com/post/186109578092

No comments:

Post a Comment